naa a22 4500 510763510 CHVBK 20180411083148.0 cr unu---uuuuu 180411e20130701xx s 000 0 eng 10.1007/s12094-012-0972-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0972-2 Upregulation of microRNA-224 confers a poor prognosis in glioma patients [Elektronische Daten] [S. Lu, S. Wang, S. Geng, S. Ma, Z. Liang, B. Jiao] Objective: MicroRNA-224 (miR-224) has been consistently reported to be dysregulated in various human malignancies and can potentially affect many cancer-related cellular processes, including transcription, cell differentiation, cell death, growth, and cell proliferation. However, its roles in human glioma have not been reported. The aim of this study was to explore the expression pattern, clinical significance, and prognostic value of miR-224 in glioma patients using large cohorts. Methods: Quantitative real-time polymerase chain reaction analysis was used to characterize the expression patterns of miR-224 in 108 glioma and 20 normal brain tissues. The associations of miR-224 expression with clinicopathological factors and prognosis of glioma patients were also statistically analyzed. Results: miR-224 expression is significantly upregulated in glioma tissues compared with normal brain tissues (P<0.001). In addition, high expression of miR-224 was significantly associated with advanced pathological grade (P=0.006) and low Karnofsky performance score (KPS, P=0.01). Moreover, Kaplan-Meier survival analysis showed that high miR-224 expression group had significantly shorter disease-free survival (DFS) and overall survival (OS) rates than low miR-224 expression group (both P<0.001). Multivariate analysis with the Cox's proportional hazards model revealed that high expression of miR-224 (P=0.006 and P=0.01, respectively) and advanced pathological grade (both P=0.02) were independent factors for shorter DFS and OS. Furthermore, subgroup analyses showed that miR-224 expression was significantly associated with poor DFS and OS in glioma patients with high pathological grades (for grade III-IV: P<0.001 and P=0.005, respectively). Conclusions: MiR-224 is upregulated and confers a poor prognosis in glioma patients. Federación de Sociedades Españolas de Oncología (FESEO), 2012 microRNA-224 nationallicence Glioma nationallicence Disease-free survival nationallicence Overall survival nationallicence Lu S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Wang S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Geng S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Ma S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Liang Z. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Jiao B. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 569-574 1699-048X 15:7<569 2013 15 12094 https://doi.org/10.1007/s12094-012-0972-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0972-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lu S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Wang S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Geng S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Ma S. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Liang Z. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Jiao B. Department of Neurosurgery, Second Hospital of Hebei Medical University, No. 215, Hepingxi Road, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 569-574 1699-048X 15:7<569 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer